Development of autologous iPS cell-derived myocardial spheres
First written in FY2024. 1 of 3 entries say "Restated". Latest entry: 2026-03-27.
No other company in this theme has enough history to compare yet.
- 2026-03-27AdvancedManagement Planning
「The Company has completed development of the underlying technology for HS-040, an autologous iPS cell-derived cardiac muscle sphere product.」
For HS-040, the Company stated that it had completed development of the underlying technology, adding to its previous description of the program as being at the basic research stage. - FY2025RestatedAnnual report
「For HS-040, we are developing a treatment using autologous iPS cell-derived cardiomyocytes, created by establishing iPS cells from the patient's own cells and differentiating and purifying the cells into cardiomyocytes. The development stage is basic research.」
HS-040 continues as a next-generation pipeline in the basic research stage, using autologous iPS cell-derived myocardial spheres. - FY2024First statedAnnual report
「For HS-040, we are developing a treatment using autologous iPS cell-derived cardiomyocytes, created by establishing an iPS cell master line from the patient's own cells and differentiating and purifying the cells into cardiomyocytes. The development stage is basic research.」
Autologous iPS cell-derived myocardial spheres using patients' own cells are being pursued as a next-generation product in the basic research stage.